In 2025, more than 140 drugs will reach the end of their Orange Book exclusivities. These exclusivities have protected these medications from generic competition, but as they expire, it opens the door for generics to enter the market. This could lead to more affordable options for patients and significant shifts in the pharmaceutical industry. On this page, we list the drugs whose exclusivities are set to expire in 2025, marking an important moment for both manufacturers and consumers.